About CQDM
Structure and Governance
Board of Directors
The Board of Directors is made up of representatives from the industry, the academic milieu and the government. The Board has the power to create committees that are deemed relevant with regard to governance, strategy, financing and account auditing, among others.
Chairman
Léon Gosselin
Co-founder of Axcan Pharma
Directors
Jennifer Chan
Vice President, Policy and Communications, Merck Canada
Michel Chrétien
Emeritus Reseach Professor, Institut de recherches cliniques de Montréal
Michael Cordingley
Senior Vice-President, Research and Development, Boehringer Ingelheim Canada
Jean Davignon
Professor, Université de Montréal
Richard Fajzel
General Manager, Oncolgy Business Unit, Pfizer Canada Inc.
Max Fehlmann
President and Chief Executive Officer, NeoMed Institute
Marc Zarenda
Scientific Director, AstraZeneca
Canada Inc.
Donald Olds
President and CEO, Presagia Corporation
Vassilios Papadopoulos
Director, Research Institute of the McGill University Health Center (MUHC)
Ken Pastor
General Partner, CTI Capital
Secretary
François Painchaud
Lawyer, Partner, ROBIC, LLP
Honorary Members
John Helou
President, Pfizer Canada Inc.
Elaine Campbell
President and CEO, AstraZeneca Canada Inc.
Remi Quirion
Chief Scientist, Fonds de recherche du Québec
Cyril Schiever
President and Managing Director, Merck Canada Inc.
Observers
Marco Blouin
Director - Industrial research, Ministere de l'enseignement superieur, de la recherche, de la science
et de la technologie
Stéphanie Michaud
Networks of Centres of Excellence